• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, November 21, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Rare Breast Malignancy Study Analyzes Clinical Features and Outcomes Across 97 Cases

by
November 20, 2026
in Cancer, Health
Reading Time: 3 mins read
0
Rare Breast Malignancy Study Analyzes Clinical Features and Outcomes Across 97 Cases

Rare Breast Malignancy Study Analyzes Clinical Features and Outcomes Across 97 Cases

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A comprehensive study has detailed the clinical features, treatment patterns, and prognostic outcomes of malignant adenomyoepithelioma of the breast, an exceptionally rare biphasic tumor. Because the disease exhibits uncertain biological behavior and clinical evidence has historically been limited, the investigation was designed to systematically clarify its presentation, pathological profile, and long-term survival trajectories.

The researchers compiled data across a wide multi-decade timeframe by systematically reviewing published medical literature from 2000 through 2026. This extensive literature search identified 48 eligible studies that collectively encompassed 86 patients. To strengthen the depth and diagnostic consistency of the investigation, the authors incorporated 11 additional patient cases treated directly at their own clinical institution, bringing the final analytical cohort to 97 patients.

From the combined records, the investigators extracted comprehensive variables covering patient demographics, primary tumor characteristics, detailed immunophenotypes, specific molecular alterations, surgical approaches, and ultimate clinical outcomes. The demographic assessment demonstrated a heavy female predominance, with the patient cohort consisting of 96 female patients and 1 male patient, exhibiting an overall median age of 58 years at diagnosis.

Immunophenotypic evaluations revealed that the tumors predominantly displayed a triple-negative receptor profile. Specifically, estrogen receptor expression was absent in 76.8 percent of evaluated cases, progesterone receptor was negative in 86.2 percent, and human epidermal growth factor receptor 2 testing was negative in 98.2 percent. In contrast, characteristic diagnostic markers showed remarkably high positivity rates across the sample, with P63 positive in 100 percent of cases, cytokeratin 5/6 positive in 97.0 percent, and cytokeratin 7 positive in 94.4 percent.

Molecular profiling conducted in the series identified recurrent genetic alterations that may carry therapeutic relevance for future patient management. Among the tested tumors, molecular alterations included HRAS mutations in four cases and PIK3CA mutations in three cases. The investigators noted that discovering these specific alterations provides potential therapeutic targets for this uncommon tumor type.

Surgical intervention served as the primary clinical treatment pattern across the cohort, split almost evenly between breast-conserving surgery in 48.7 percent of patients and complete mastectomy in 51.3 percent. Notably, axillary lymph node metastasis was rare among the evaluated cases. The authors emphasized that complete surgical resection remains the fundamental cornerstone of clinical management, while individualized adjuvant therapy should be considered based on high-risk pathological features.

Over a median clinical follow-up duration of 35 months, documented disease recurrence and survival outcomes demonstrated distinct clinical risks. Local recurrence occurred in 5.8 percent of patients, while distant hematogenous metastasis was documented in 16.3 percent, and overall mortality reached 5.8 percent. Given the rarity of the malignancy and the risks of recurrence, the authors concluded that further large-scale collaborative studies are necessary to establish standardized, evidence-based treatment regimens and robust prognostic models.

Subject of Research: Clinical, pathological, and prognostic characteristics of breast malignant adenomyoepithelioma

Article Title: Malignant adenomyoepithelioma of the breast: clinicopathological features, treatment patterns, and prognostic implications in 97 cases

Article References: Xian, K., Wang, X., Lu, Y., Li, Z., Zhang, W., Wang, Z., Kong, X., & Wang, J. (2026). Malignant adenomyoepithelioma of the breast: clinicopathological features, treatment patterns, and prognostic implications in 97 cases. Breast Cancer Research. https://doi.org/10.1186/s13058-026-02408-3

Image Credits: AI Generated

DOI: 10.1186/s13058-026-02408-3

Keywords: malignant adenomyoepithelioma, breast cancer, biphasic tumor, triple-negative breast cancer, estrogen receptor, progesterone receptor, HER-2, P63, CK7, CK5/6, HRAS mutations, PIK3CA mutations, breast-conserving surgery, mastectomy, axillary lymph node metastasis, local recurrence, hematogenous metastasis, prognostic implications

News Source: Nathaniel Bowman. (November 20, 2026). Rare Breast Malignancy Study Analyzes Clinical Features and Outcomes Across 97 Cases. Scienmag.

Tags: axillary lymph-node metastasisbiphasic tumorBreast Cancerbreast-conserving surgeryCK5/6CK7estrogen receptorhematogenous metastasisHER-2HRAS mutationslocal recurrencemalignant adenomyoepitheliomamastectomyp63PIK3CA mutationsprogesterone receptorPrognostic implicationstriple-negative breast cancer
Share12Tweet7Share2ShareShareShare1

Related Posts

Hyperdominant Left Anterior Descending Artery Can Cause Multi-Territorial Myocardial Ischemia

Hyperdominant Left Anterior Descending Artery Can Cause Multi-Territorial Myocardial Ischemia

November 21, 2026
Kaempferol Reduces Cardiac Fibrosis and Improves Ejection Fraction in Mice

Kaempferol Reduces Cardiac Fibrosis and Improves Ejection Fraction in Mice

November 21, 2026

Dexamethasone Implant Shows No Six-Month Benefit in Epiretinal Membrane Surgery

November 21, 2026

Standardized Framework Classifies Rare KCNMA1 Gene Variants Linked to Neurological Channelopathies

November 21, 2026

POPULAR NEWS

  • Nationwide Survey Shows Chinese Quality of Life Rebounded After Omicron Wave

    Nationwide Survey Shows Chinese Quality of Life Rebounded After Omicron Wave

    29 shares
    Share 12 Tweet 7
  • Non-invasive embryo genetic testing does not improve ongoing pregnancy rates in trial

    29 shares
    Share 12 Tweet 7
  • Comprehensive Review Details Multicellular Mechanisms Driving Primary Sclerosing Cholangitis Progression

    29 shares
    Share 12 Tweet 7
  • Study Links Fecal Enterococcus and Tyramine in Subacute Hypertensive Brain Hemorrhage

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Spatial Skip-Connected Attention Model Accurately Predicts Urban Traffic From Air Quality

Hyperdominant Left Anterior Descending Artery Can Cause Multi-Territorial Myocardial Ischemia

Kaempferol Reduces Cardiac Fibrosis and Improves Ejection Fraction in Mice

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.